Boxed warning on Zogenix’s Dravet syndrome therapy could hamper market prospects

Agency rebuffs wet AMD therapy from AbbVie, Molecular Partners, approves Chiasma’s oral acromegaly drug

FDA’s approval of a resubmitted NDA for Fintepla to treat seizures associated with Dravet syndrome sets Zogenix up to compete with GW’s Epidiolex in the rare epilepsy market, but the drug’s prospects may be hampered by a boxed warning on

Read the full 401 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE